Price Movement and Market Context
On 25 Nov 2025, Shree Ganesh Biotech India’s stock price touched Rs.0.62, representing its lowest point in the past year and also an all-time low. This decline comes despite the broader market showing resilience, with the Sensex opening higher at 85,008.93 and trading near its 52-week high of 85,801.70. The Sensex was up by 0.13% at the open and was trading at 84,957.75, just 0.07% below the opening level during the day.
In contrast to the Sensex’s positive momentum, Shree Ganesh Biotech India underperformed its sector, the Pharmaceuticals & Biotechnology industry, by 2.14% on the same day. The stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward pressure. Meanwhile, the Agriculture sector, a related area, recorded gains of 3.8%, highlighting the divergence in sectoral performance.
Financial Performance and Key Metrics
Over the past year, Shree Ganesh Biotech India’s stock has recorded a return of -38.46%, contrasting with the Sensex’s positive 6.05% return over the same period. The stock’s 52-week high was Rs.1.19, indicating a substantial decline from its peak.
The company’s financial results for the nine months ended 25 Sep 2025 reveal a contraction in net sales to Rs.5.16 crores, reflecting a reduction of 44.64% compared to the previous period. Correspondingly, the profit after tax (PAT) stood at a loss of Rs.0.61 crores, also showing a decline of 44.64%. These figures point to a challenging revenue environment and pressure on profitability.
Liquidity and Debt Servicing
Shree Ganesh Biotech India’s ability to service its debt remains constrained, with an average EBIT to interest ratio of 0.91, indicating limited earnings relative to interest obligations. The company’s return on equity (ROE) averaged 2.62%, suggesting modest profitability relative to shareholders’ funds.
Additionally, the debtors turnover ratio for the half-year period was recorded at 0.00 times, signalling potential issues in receivables management or collection efficiency. The company’s earnings before interest, taxes, depreciation and amortisation (EBITDA) have been negative, which adds to the financial risk profile of the stock.
Fundamentals that don't lie! This Small Cap from Trading shows consistent growth and price strength over time. A reliable pick you can truly count on.
- - Strong fundamental track record
- - Consistent growth trajectory
- - Reliable price strength
Shareholding and Market Position
The majority of Shree Ganesh Biotech India’s shares are held by non-institutional investors, which may influence the stock’s trading dynamics and liquidity. The company operates within the Pharmaceuticals & Biotechnology sector, which has seen mixed performance in recent times.
Despite the broader market’s positive trend, mid-cap stocks have led gains with the BSE Mid Cap index rising by 0.16% on the day, yet Shree Ganesh Biotech India’s stock has not mirrored this trend, reflecting sector-specific or company-specific pressures.
Valuation and Risk Considerations
The stock is currently trading at levels that suggest elevated risk compared to its historical valuations. Over the past year, profits have declined by approximately 86.6%, underscoring the financial strain on the company. The combination of negative EBITDA and weak debt servicing capacity contributes to the cautious market assessment of the stock.
Holding Shree Ganesh Biotech India from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Current Situation
Shree Ganesh Biotech India’s stock reaching a 52-week low of Rs.0.62 reflects a combination of subdued financial results, weak profitability metrics, and challenges in debt servicing. The stock’s performance contrasts with the broader market and sector trends, which have shown relative strength in recent sessions.
Investors and market participants observing this stock will note the divergence from the Sensex’s positive trajectory and the Pharmaceuticals & Biotechnology sector’s mixed performance. The company’s financial indicators highlight areas of concern, including declining sales, losses, and liquidity constraints.
Market Environment
The broader market environment remains supportive, with the Sensex trading above its 50-day moving average and the 50 DMA positioned above the 200 DMA, indicating a generally bullish trend. Mid-cap stocks have shown leadership in market gains, yet Shree Ganesh Biotech India has not participated in this uplift.
Sectoral movements also show variation, with Agriculture gaining 3.8% while the Pharmaceuticals & Biotechnology sector has faced headwinds. This sectoral divergence further contextualises the stock’s performance within its industry landscape.
Conclusion
The fall of Shree Ganesh Biotech India’s stock to its 52-week low of Rs.0.62 marks a notable development in its market journey. The company’s financial data and market positioning provide a factual basis for understanding the stock’s current valuation and trading behaviour. While the broader market and sector indices have shown resilience, this stock’s trajectory highlights the challenges it faces in the current environment.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
